Mark Wildgust: Outstanding Results from the FLAIR Study Presented at EHA25
Mark Wildgust, Vice President, Global Medical Affairs, Oncology at The Janssen Pharmaceutical Companies of Johnson and Johnson, shared a post on X:
“Outstanding results from the FLAIR study presented at EHA25 today and published in the NEJM.”
Title: Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
Journal: NEJM
Authors: Talha Munir, Sean Girvan, David A. Cairns, Adrian Bloor, David Allsup, Abraham M. Varghese, Satyen Gohil, Shankara Paneesha, Andrew Pettitt, Toby Eyre, Christopher P. Fox, Francesco Forconi, Constantine Balotis, Nicholas Pemberton, Oonagh Sheehy, John Gribben, Nagah Elmusharaf, Simona Gatto, Gavin Preston, Anna Schuh, Renata Walewska, Lelia Duley, Nichola Webster, Surita Dalal, Andrew Rawstron, Dena Howard, Anna Hockaday, Sharon Jackson, Natasha Greatorex, Sue Bell, David Stones, Julia M. Brown, Piers E.M. Patten, Peter Hillmen
Take a moment to look 25 Posts Not to Miss from EHA 2025
-
Jan 4, 2026, 17:02Oğuzhan Işılay on Stabilizing Human Blood Clotting Factor VIII
-
Jan 4, 2026, 16:48Sleep Apnea: Full Breakdown from John Chuback
-
Jan 4, 2026, 16:36Edwin Ofori Atta on Permissive Hypertension For Ischemic Stroke
-
Jan 4, 2026, 16:27Nasrin Haghani on The Milli-Spinners: Breakthrough Technology Transforming Stroke Clot Removal
-
Jan 4, 2026, 16:10Godfrey Gandawa on Neuroplasticity in Stroke Rehabilitation
-
Jan 4, 2026, 14:53What Do Blood and Plasma Donors Think About Biobanking? A New Study Reveals Their Attitudes
-
Jan 4, 2026, 14:51First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
-
Jan 4, 2026, 14:51Shreya Agrawal: Top 5 Practical Hematology Lessons from 2025 – Mild Cytopenias are Rarely “Incidental” and More
-
Jan 4, 2026, 14:46We Analyzed Data From the Start of the COVID-19 Pandemic to 2024 – What Did We find?